<p>Kalaris Therapeutics Inc.（纳斯达克代码：KLRS - 获取免费报告）在一月份的空头头寸大幅增加。截至 1 月 15 日，空头头寸总计 867,767 股，比 12 月 31 日的 539,567 股增加了 60.8%。该公司约有 18.6% 的股票被卖空。根据平均交易量 100,271 股，目前的覆盖天数比率为 8.7 天。</p>
<p>获取 <strong>Kalaris Therapeutics</strong> 的提醒：</p>
<h2>对 Kalaris Therapeutics 的对冲基金看法</h2>
<p>大型投资者最近增加或减少了对该公司的持股。Johnson Financial Group Inc. 在第三季度购买了价值 58,000 美元的 Kalaris Therapeutics 新股份。XTX Topco Ltd 在第二季度购买了价值约 65,000 美元的 Kalaris Therapeutics 新股份。Bridgeway Capital Management LLC 在第三季度收购了价值约 130,000 美元的 Kalaris Therapeutics 新股份。Belpointe Asset Management LLC 在第三季度购买了价值约 231,000 美元的 Kalaris Therapeutics 新股份。最后，Fortis Capital Advisors LLC 在第三季度购买了价值约 231,000 美元的 Kalaris Therapeutics 新股份。目前 66.05% 的股票由机构投资者持有。</p>
<h2>分析师设定新目标价</h2>
<p>一些分析师最近对 KLRS 股票发布了报告。Citizens Jmp 在 11 月 3 日的研究报告中开始覆盖 Kalaris Therapeutics 的股票。他们对该股票设定了 “市场表现优于大盘” 的评级和 20.00 美元的目标价。花旗集团在 12 月 18 日的报告中重申了对 Kalaris Therapeutics 股票的 “表现优于大盘” 评级。Chardan Capital 在 12 月 23 日的报告中开始覆盖 Kalaris Therapeutics 的股票。他们对该股票发布了 “买入” 评级和 19.00 美元的目标价。Wall Street Zen 在周六的研究报告中将 Kalaris Therapeutics 的股票评级从 “持有” 下调至 “卖出”。最后，Weiss Ratings 在 12 月 29 日的研究报告中重申了对 Kalaris Therapeutics 股票的 “卖出（d-）” 评级。一位研究分析师对该股票给予了强烈买入评级，三位给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，共识目标价为 14.00 美元。</p>
<p><strong>查看我们最新的 KLRS 股票报告</strong></p>
<h2>Kalaris Therapeutics 股票表现</h2>
<p>Kalaris Therapeutics 股票在周五的交易中下跌 0.32 美元，达到 8.88 美元。该公司的交易量为 43,068 股，而其平均交易量为 74,560 股。Kalaris Therapeutics 的 52 周低点为 2.14 美元，52 周高点为 12.90 美元。该公司的 50 日移动平均线为 8.42 美元，200 日移动平均线为 5.72 美元。公司的市值为 1.6606 亿美元，市盈率为-2.36，贝塔值为-0.09。</p>
<p>Kalaris Therapeutics（纳斯达克代码：KLRS - 获取免费报告）最后一次公布季度财报是在 11 月 12 日，报告每股收益（EPS）为-0.64 美元，超出市场共识预期的-0.66 美元 0.02 美元。</p>
<h2>Kalaris Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Allovir, Inc. 是一家临床阶段的细胞治疗公司，专注于研发同种异体、现成的多病毒特异性 T 细胞（VST）疗法，以预防和治疗严重的病毒相关疾病。该公司的主要产品是 posoleucel，一种同种异体、现成的 VST 疗法，用于治疗 BK 病毒、巨细胞病毒、腺病毒、埃布斯坦 - 巴尔病毒、人类疱疹病毒 6 和 JC 病毒。其临床前和临床开发的产品候选包括 ALVR106，用于呼吸道合胞病毒、流感、副流感病毒和人类副流感病毒；ALVR109 用于治疗 SARS-CoV-2 和 COVID-19；ALVR107 用于治疗乙型肝炎；以及 ALVR108。</p>
<h2>阅读更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 Kalaris Therapeutics</li>
<li>请勿删除，立即阅读</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>用这四个简单步骤 “防止” 你的银行账户受到影响</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>崩盘已经开始（大多数人只是还没看到）</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Kalaris Therapeutics 吗？</h2>
<p>在考虑 Kalaris Therapeutics 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而 Kalaris Therapeutics 并不在名单上。</p>
<p>虽然 Kalaris Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

KLRS

<p>Kalaris Therapeutics Inc.（纳斯达克代码：KLRS）在 1 月 15 日的空头头寸显著增加，增长了 60.8%，达到 867,767 股。这大约占公司股票的 18.6% 被做空，基于每日平均交易量 100,271 股，覆盖天数比率为 8.7 天。机构投资者持有 66.05% 的股份，分析师的评级意见不一，普遍目标价为 14.00 美元。该股票交易价格为 8.88 美元，市值为 1.6606 亿美元，市盈率为-2.36</p>

<p>Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totaling 867,767 shares, an increase of 60.8% from the December 31st total of 539,567 shares. Approximately 18.6% of the company's stock are sold short. Based on an average trading volume of 100,271 shares, the days-to-cover ratio is presently 8.7 days. Based on an average trading volume of 100,271 shares, the days-to-cover ratio is presently 8.7 days. Approximately 18.6% of the company's stock are sold short.</p>
<div class="lb-trans"><p>Kalaris Therapeutics Inc.（纳斯达克代码：KLRS - 获取免费报告）在一月份的空头头寸大幅增加。截至 1 月 15 日，空头头寸总计 867,767 股，比 12 月 31 日的 539,567 股增加了 60.8%。该公司约有 18.6% 的股票被卖空。根据平均交易量 100,271 股，目前的覆盖天数比率为 8.7 天。</p>
</div><p>Get <strong>Kalaris Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Kalaris Therapeutics</strong> 的提醒：</p>
</div><h2>Hedge Funds Weigh In On Kalaris Therapeutics</h2>
<div class="lb-trans"><h2>对 Kalaris Therapeutics 的对冲基金看法</h2>
</div><p>Large investors have recently added to or reduced their stakes in the company. Johnson Financial Group Inc. bought a new stake in Kalaris Therapeutics during the third quarter valued at $58,000. XTX Topco Ltd bought a new position in shares of Kalaris Therapeutics in the 2nd quarter worth about $65,000. Bridgeway Capital Management LLC acquired a new position in shares of Kalaris Therapeutics in the 3rd quarter valued at about $130,000. Belpointe Asset Management LLC bought a new stake in shares of Kalaris Therapeutics during the 3rd quarter valued at about $231,000. Finally, Fortis Capital Advisors LLC bought a new stake in shares of Kalaris Therapeutics during the 3rd quarter valued at about $231,000. 66.05% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>大型投资者最近增加或减少了对该公司的持股。Johnson Financial Group Inc. 在第三季度购买了价值 58,000 美元的 Kalaris Therapeutics 新股份。XTX Topco Ltd 在第二季度购买了价值约 65,000 美元的 Kalaris Therapeutics 新股份。Bridgeway Capital Management LLC 在第三季度收购了价值约 130,000 美元的 Kalaris Therapeutics 新股份。Belpointe Asset Management LLC 在第三季度购买了价值约 231,000 美元的 Kalaris Therapeutics 新股份。最后，Fortis Capital Advisors LLC 在第三季度购买了价值约 231,000 美元的 Kalaris Therapeutics 新股份。目前 66.05% 的股票由机构投资者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of analysts have recently issued reports on KLRS shares. Citizens Jmp started coverage on shares of Kalaris Therapeutics in a research note on Monday, November 3rd. They set a &#34;market outperform&#34; rating and a $20.00 price objective on the stock. Citigroup reaffirmed an &#34;outperform&#34; rating on shares of Kalaris Therapeutics in a report on Thursday, December 18th. Chardan Capital started coverage on shares of Kalaris Therapeutics in a report on Tuesday, December 23rd. They issued a &#34;buy&#34; rating and a $19.00 price objective on the stock. Wall Street Zen cut shares of Kalaris Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday. Finally, Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Kalaris Therapeutics in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $14.00.</p>
<div class="lb-trans"><p>一些分析师最近对 KLRS 股票发布了报告。Citizens Jmp 在 11 月 3 日的研究报告中开始覆盖 Kalaris Therapeutics 的股票。他们对该股票设定了 “市场表现优于大盘” 的评级和 20.00 美元的目标价。花旗集团在 12 月 18 日的报告中重申了对 Kalaris Therapeutics 股票的 “表现优于大盘” 评级。Chardan Capital 在 12 月 23 日的报告中开始覆盖 Kalaris Therapeutics 的股票。他们对该股票发布了 “买入” 评级和 19.00 美元的目标价。Wall Street Zen 在周六的研究报告中将 Kalaris Therapeutics 的股票评级从 “持有” 下调至 “卖出”。最后，Weiss Ratings 在 12 月 29 日的研究报告中重申了对 Kalaris Therapeutics 股票的 “卖出（d-）” 评级。一位研究分析师对该股票给予了强烈买入评级，三位给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的平均评级为 “适度买入”，共识目标价为 14.00 美元。</p>
</div><p><strong>View Our Latest Stock Report on KLRS</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 KLRS 股票报告</strong></p>
</div><h2>Kalaris Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Kalaris Therapeutics 股票表现</h2>
</div><p>Shares of Kalaris Therapeutics stock traded down $0.32 during trading on Friday, reaching $8.88. The company had a trading volume of 43,068 shares, compared to its average volume of 74,560. Kalaris Therapeutics has a fifty-two week low of $2.14 and a fifty-two week high of $12.90. The firm's fifty day moving average is $8.42 and its 200-day moving average is $5.72. The company has a market cap of $166.06 million, a price-to-earnings ratio of -2.36 and a beta of -0.09.</p>
<div class="lb-trans"><p>Kalaris Therapeutics 股票在周五的交易中下跌 0.32 美元，达到 8.88 美元。该公司的交易量为 43,068 股，而其平均交易量为 74,560 股。Kalaris Therapeutics 的 52 周低点为 2.14 美元，52 周高点为 12.90 美元。该公司的 50 日移动平均线为 8.42 美元，200 日移动平均线为 5.72 美元。公司的市值为 1.6606 亿美元，市盈率为-2.36，贝塔值为-0.09。</p>
</div><p>Kalaris Therapeutics (NASDAQ:KLRS - Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.02.</p>
<div class="lb-trans"><p>Kalaris Therapeutics（纳斯达克代码：KLRS - 获取免费报告）最后一次公布季度财报是在 11 月 12 日，报告每股收益（EPS）为-0.64 美元，超出市场共识预期的-0.66 美元 0.02 美元。</p>
</div><h2>Kalaris Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Kalaris Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.</p>
<div class="lb-trans"><p>Allovir, Inc. 是一家临床阶段的细胞治疗公司，专注于研发同种异体、现成的多病毒特异性 T 细胞（VST）疗法，以预防和治疗严重的病毒相关疾病。该公司的主要产品是 posoleucel，一种同种异体、现成的 VST 疗法，用于治疗 BK 病毒、巨细胞病毒、腺病毒、埃布斯坦 - 巴尔病毒、人类疱疹病毒 6 和 JC 病毒。其临床前和临床开发的产品候选包括 ALVR106，用于呼吸道合胞病毒、流感、副流感病毒和人类副流感病毒；ALVR109 用于治疗 SARS-CoV-2 和 COVID-19；ALVR107 用于治疗乙型肝炎；以及 ALVR108。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Kalaris Therapeutics</li>
<li>Do not delete, read immediately</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Kalaris Therapeutics</li>
<li>请勿删除，立即阅读</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>用这四个简单步骤 “防止” 你的银行账户受到影响</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>崩盘已经开始（大多数人只是还没看到）</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Kalaris Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Kalaris Therapeutics 吗？</h2>
</div><p>Before you consider Kalaris Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Kalaris Therapeutics 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kalaris Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而 Kalaris Therapeutics 并不在名单上。</p>
</div><p>While Kalaris Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Kalaris Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Kalaris Therapeutics Inc.（NASDAQ:KLRS）的空头头寸增加了 60.8%